Glucocorticoids and prostate cancer treatment: Friend or foe?

Asian Journal of Andrology

Volumn 16, Issue 3, 2014, Pages 354-358

  Montgomery, Bruce ^a   Cheng, Heather H ^a   Drechsler, James ^b   Mostaghel, Elahe A ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SEATTLE CANCER CARE ALLIANCE   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Androgen receptor; Dihydrotestosterone; Glucocorticoid receptor; Glucocorticoids; Prostate cancer; Steroids; Testosterone

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; CORTISONE; DEOXYCORTICOSTERONE; DEXAMETHASONE; DIETHYLSTILBESTROL; DOCETAXEL; ENZALUTAMIDE; FLUTAMIDE; GESTAGEN; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HYDROCORTISONE; MITOXANTRONE; PLACEBO; PREDNISONE; SATRAPLATIN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CASTRATION RESISTANT PROSTATE CANCER; DISEASE COURSE; HORMONAL THERAPY; HUMAN; NONHUMAN; OVERALL SURVIVAL; REVIEW; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; MALE; METABOLISM; MUTATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT;

ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; CLINICAL TRIALS AS TOPIC; GLUCOCORTICOIDS; HUMANS; MALE; MUTATION; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, GLUCOCORTICOID;

EID: 84900513764     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.4103/1008-682X.125392     Document Type: Review

References (49)

1. Tenbaum S, Baniahmad A. Nuclear receptors: Structure, function and involvement in Disease. Int J Biochem Cell Biol 1997; 29: 1325-41
2. Kfir-Erenfeld S, Yefenof E. Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis. Cancer Immunol Immunother 2014; 63: 37-43
3. Piccart MJ, Klijn J, Paridaens R, Nooij M, Mauriac L, et al. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol 1997; 15: 3149-55
4. Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, et al. Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer. J Clin Endocrinol Metab 2012; 97: 507-16
5. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1: 293-7
6. Alder A, Burger H, Davis J, Dulmanis A, Hudson B, et al. Carcinoma of prostate: Response of plasma luteinizing hormone and testosterone to oestrogen therapy. Br Med J 1968; 1: 28-30
7. Tomic R, Ljungberg B, Damber JE. Hormonal effects of high dose medroxyprogesterone acetate treatment in males with renal or prostatic adenocarcinoma. Scand J Urol Nephrol 1988; 22: 15-8
8. Alesci S, Koch CA, Bornstein SR, Pacak K. Adrenal androgens regulation and adrenopause. Endocrine regulations 2001; 35: 95-100
9. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005; 23: 8253-61
10. Harrison JH, Thorn GW, Jenkins D. Total adrenalectomy for reactivated carcinoma of the prostate. N Engl J Med 1953; 248: 86-92
11. Kirschner MA, Knorr DW. Suppression of androgen and oestrogen production in normal men. Acta Endocrinol (Copenh) 1972; 70: 342-50
12. Denayer S, Helsen C, Thorrez L, Haelens A, Claessens F. The rules of DNA recognition by the androgen receptor. Mol Endocrinol 2010; 24: 898-913
13. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol Endocrinol 1993; 7: 1541-50
14. Chang CY, Walther PJ, McDonnell DP. Glucocorticoids manifest androgenic activity in a cell line derived from a metastatic prostate cancer. Cancer Res 2001; 61: 8712-7
15. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, et al. Novel mutations of androgen receptor: Possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-53
16. Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, et al. Interactions of abiraterone, eplerenone, and prednisolone with wild-Type and mutant androgen receptor: Rationale for increasing abiraterone exposure or combining with MDV3100 Cancer Res 2012; 72: 2176-82
17. Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, et al. Cancer and Leukemia Group B Study 9663 Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663. J Clin Oncol 2003; 21: 2673-8
18. Sahu B, Laakso M, Pihlajamaa P, Ovaska K, Sinielnikov I, et al. FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells. Cancer Res 2013; 73: 1570-80
19. Sahu B, Laakso M, Ovaska K, Mirtti T, Lundin J, et al. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. Embo J 2011; 30: 3962-76
20. Arora VK, Schenkein E, Murali R, Subudhi SK, Wongvipat J, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-22
21. Wilding G. Response of prostate cancer cells to peptide growth factors: Transforming growth factor-beta. Cancer Surv 1991; 11: 147-63
22. Reyes-Moreno C, Frenette G, Boulanger J, Lavergne E, Govindan MV, et al. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate 1995; 26: 260-9
23. Li Z, Chen Y, Cao D, Wang Y, Chen G, et al. Glucocorticoid up-regulates transforming growth factor-beta (TGF-beta) type II receptor and enhances TGF-beta signaling in human prostate cancer PC-3 cells. Endocrinology 2006; 147: 5259-67
24. Culig Z, Puhr M. Interleukin-6: Multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 2012; 360: 52-8
25. Nishimura K, Nonomura N, Satoh E, Harada Y, Nakayama M, et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. J Natl Cancer Inst 2001; 93: 1739-46
26. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, et al. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-Activated protein kinase pathway. Am J Pathol 2003; 162: 655-63
27. Rojas A, Liu G, Coleman I, Nelson PS, Zhang M, et al. IL-6 promotes prostate tumorigenesis and progression through autocrine cross-Activation of IGF-IR. Oncogene 2011; 30: 2345-55
28. Yano A, Fujii Y, Iwai A, Kawakami S, Kageyama Y, et al. Glucocorticoids suppress tumor lymphangiogenesis of prostate cancer cells. Clin Cancer Res 2006; 12: 6012-7
29. Tannock I, Gospodarowicz M, Meakin W, Panzarella T, Stewart L, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7: 590-7
30. Kelly WK, Curley T, Leibretz C, Dnistrian A, Schwartz M, et al. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 1995; 13: 2208-13
31. Storlie JA, Buckner JC, Wiseman GA, Burch PA, Hartmann LC, et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer 1995; 76: 96-100
32. Venkitaraman R, Thomas K, Huddart RA, Horwich A, Dearnaley DP, et al. Efficacy of low-dose dexamethasone in castration-refractory prostate cancer. BJU Int 2008; 101: 440-3
33. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756-64
34. Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study. J Clin Oncol 1999; 17: 2506-13
35. Fossa SD, Slee PH, Brausi M, Horenblas S, Hall RR, et al. Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-Ablative therapy: Phase III study of the European organization for research and treatment of cancer genitourinary group. J Clin Oncol 2001; 19: 62-71
36. Shamash J, Powles T, Sarker SJ, Protheroe A, Mithal N, et al. A multi-centre randomised phase III trial of Dexamethasone vs Dexamethasone and diethylstilbestrol in castration-resistant prostate cancer: Immediate vs deferred Diethylstilbestrol. Br J Cancer 2011; 104: 620-8
37. Ryan CJ, Molina A, Griffin T. Abiraterone in metastatic prostate cancer. N Engl J Med 2013; 368: 1458-9
38. Sternberg CN, Petrylak DP, Sartor O, Witjes JA, Demkow T, et al. Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: The SPARC trial. J Clin Oncol 2009; 27: 5431-8
39. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, et al. COU-AA-301 Investigators Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995-2005
40. Weitzman AL, Shelton G, Zuech N, Owen CE, Judge T, et al. Dexamethasone does not significantly contribute to the response rate of docetaxel and estramustine in androgen independent prostate cancer. J Urol 2000; 163: 834-7
41. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26: 4563-71
42. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, et al., TÄ.327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12
43. Scher HI, Jia X, Chi K, de Wit R, Berry WR, et al. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol 2011; 29: 2191-8
44. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012; 30: 1534-40
45. Tannock IF, Fizazi K, Ivanov S, Karlsson CT, Flechon A, et al. VENICE investigators Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): Phase 3, double-blind randomised trial. Lancet Oncol 2013; 14: 760-8
46. Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). Proc Am Soc Clin Onc 2009
47. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, et al. AFFIRM Investigators Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-97
48. Scher HI, Fizazi K, Saad F, Chi K, Taplin ME, et al. Association of baseline corticosteroid with outcomes in amultivariate analysis of the phase 3 affirm study of Enzalutamide (ENZA), an androgen receptor signaling inhibitor (ARSI). Proc ESMO 2012
49. Montgomery B, Kheoh S, Molina A, Li J, Bellmunt J, et al. Effect of corticosteroid (CS) use at baseline (CUB) on overall survival (OS) in patients (pts) receiving abiraterone acetate (AA): Results from a randomized study (COU-AA-301) in metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel (D). Proc ASCO 2013.